A Study of Tarlatamab for People With Prostate Cancer

The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).

Trial Details

NCT ID
NCT07111507
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Tarlatamab
Locations (sample)
  • San Diego, California, United States|32.71571,-117.16472
  • San Francisco, California, United States|37.77493,-122.41942
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292

Key Eligibility Criteria

  • To be included in this study, participants should complete all screening procedures and meet all of the following criteria:
  • Willing and able to provide, or have a legally authorized representative provide, written informed consent and privacy authorization for the releas…
  • NOTE: Privacy authorization may be either included in the informed consent or obtained separately.
  • 18 years of age and above

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →